News

The Mochi Health Lawsuit, Explained

Eli Lilly sued Mochi Health over compounded and "personalized-dose" GLP-1s. What the suit claims, what it means if you're a Mochi patient, and what happens next.

Reading time
1 minute read

The short answer: [Bold lede — who sued whom, over what, current status, one sentence each. Dated.]

[Intro placeholder — the compounding backdrop: FDA shortage resolution 2025, the legal basis for mass compounding ending, Lilly/Novo enforcement wave. PLAN §11 #4 stance: informational only, no compounded affiliate links.]

Key takeaways

  • [What the suit claims] — [placeholder]
  • [What it means for patients] — [placeholder]
  • [Status as of {date}] — [placeholder]

The timeline

DateWhat happened
[date][FDA declares shortage resolved]
[date][Suit filed — court, claims]
[date][Latest development]

If you’re a Mochi patient

[Placeholder — practical, non-alarmist; link the Mochi review + alternatives comparison when they exist.]


Frequently asked questions

Is Mochi Health shutting down?

[Placeholder answer — verified only.]

[Placeholder answer — link the compounded explainer.]

Spencer Lanoue

Spencer is the founder of GLP Index. He researches GLP-1 medications, providers, and pricing full-time — every page on the site crosses his desk before it publishes.

This article is for information only and isn't medical advice — talk to a licensed clinician before changing your medication, diet, or supplements. Some links may earn us a commission; it never affects what we recommend. Medical disclaimer · Editorial policy

Find the right GLP‑1 in 2 minutes

Free · No account · Independent

Take the quiz